Trial Search Results

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

The purpose of this study is to examine the safety and effectiveness of larotrectinib (LOXO-101) in pediatric patients with an advanced cancer harboring a fusion involving NTRK1, NTRK2, or NTRK3 (collective referred to as NTRK fusions). In Phase 1 of the study, increasing doses of larotrectinib will be tested to determine the recommended safe dose in children. In Phase 1 Dose Expansion and Phase 2, subjects will receive multiple cycles of larotrectinib to evaluate its efficacy in treating cancer. All participants must either have infantile fibrosarcoma or a documented NTRK fusion mutation.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott
650-497-7659
Recruiting